絞り込み

16645

広告

新型ウイルス対応医師ら職場で“バイ菌”扱い 学会が抗議声明

新型コロナウイルスの集団感染が起きたクルーズ船などで、対応を行った医師や看護師らが職場などで不当な扱いを受けているとして、災害対応を行う医療関係者でつくる学会が...

  1. 新型肺炎 インフルエンザ治療薬など使用 ...
  2. 新型肺炎 クルーズ下船後に陽性 栃木の6...
  3. 【動画】「dry cough」の意味を予...
  4. G20開幕 肺炎議題に 世界経済リスク、...

ニュース一覧

Negative Feedback Regulation of HIV-1 by Gene Editing Strategy.

著者 Kaminski R , Chen Y , Salkind J , Bella R , Young WB , Ferrante P , Karn J , Malcolm T , Hu W , Khalili K
Sci Rep.2016 ; 6():31527.
この記事をPubMed上で見るPubMedで表示
この記事をGoogle翻訳上で見る Google翻訳で開く

スターを付ける スターを付ける     (5view , 0users)

Full Text Sources

Medical

Miscellaneous

Other Literature Sources

The CRISPR/Cas9 gene editing method is comprised of the guide RNA (gRNA) to target a specific DNA sequence for cleavage and the Cas9 endonuclease for introducing breaks in the double-stranded DNA identified by the gRNA. Co-expression of both a multiplex of HIV-1-specific gRNAs and Cas9 in cells results in the modification and/or excision of the segment of viral DNA, leading to replication-defective virus. In this study, we have personalized the activity of CRISPR/Cas9 by placing the gene encoding Cas9 under the control of a minimal promoter of HIV-1 that is activated by the HIV-1 Tat protein. We demonstrate that functional activation of CRISPR/Cas9 by Tat during the course of viral infection excises the designated segment of the integrated viral DNA and consequently suppresses viral expression. This strategy was also used in a latently infected CD4+ T-cell model after treatment with a variety of HIV-1 stimulating agents including PMA and TSA. Controlled expression of Cas9 by Tat offers a new strategy for safe implementation of the Cas9 technology for ablation of HIV-1 at a very early stage of HIV-1 replication during the course of the acute phase of infection and the reactivation of silent proviral DNA in latently infected cells.
PMID: 27528385 [PubMed - as supplied by publisher]
印刷用ページを開く Endnote用テキストダウンロード